A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
3 other identifiers
interventional
640
22 countries
220
Brief Summary
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jul 2011
Typical duration for phase_3
220 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 7, 2011
CompletedFirst Posted
Study publicly available on registry
June 8, 2011
CompletedStudy Start
First participant enrolled
July 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2014
CompletedResults Posted
Study results publicly available
January 6, 2017
CompletedJanuary 6, 2017
November 1, 2016
3.1 years
June 7, 2011
September 1, 2016
November 9, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants With Clinical Response at Week 6
Clinical response at Week 6 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (\>=) 100 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). Participants with a baseline CDAI score of \> = 220 to less than or equal (\< =) 248 were considered to be in clinical response if a CDAI score of less than (\<) 150 was attained. A decrease in CDAI score over time indicates improvement in disease activity.
Week 6
Secondary Outcomes (4)
Number of Participants in Clinical Remission at Week 8
Week 8
Number of Participants in Clinical Response at Week 8
Week 8
Number of Participants With Crohn's Disease Activity Index (CDAI) 70 Point Response at Week 6
Week 6
Number of Participants With CDAI 70 Point Response at Week 3
Week 3
Study Arms (3)
Placebo IV
PLACEBO COMPARATORGroup 1: Placebo Form=solution for injection route=intravenous use in a single dose.
Ustekinumab 130 milligram (mg)
EXPERIMENTALGroup 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)
EXPERIMENTALGroup 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg) 390 mg (weight \> 55 kg and \<= 85 kg) and 520 mg (weight \> 85 kg).
Interventions
Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
Eligibility Criteria
You may qualify if:
- Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy
- Have active Crohn's disease, defined as a baseline Crohn Disease Activity Index (CDAI) score of \>= 220 and \<= 450, with confirmation of active inflammation
- Has failed conventional therapy as demonstrated by having received corticosteroids and/or immunomodulators(ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Have a history of failure to respond to or tolerate an adequate course of corticosteroids and/or immunomodulators (ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Is corticosteroid dependent or has had a history of corticosteroid dependency AND Has not previously demonstrated failure of or intolerance to 1 or more TNF-antagonist therapies (ie, infliximab, adalimumab, or certolizumab pegol) per study criteria
- Have screening laboratory test results within protocol-specified parameters
You may not qualify if:
- Patients who have had any kind of bowel resection within 6 months
- Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent
- Patients who have received infliximab, adalimumab or certolizumab pegol \< = 8 weeks before the first administration of study drug
- Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug
- Patients with a history of or ongoing chronic or recurrent infectious disease
- Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (220)
Unknown Facility
Tucson, Arizona, United States
Unknown Facility
Little Rock, Arkansas, United States
Unknown Facility
La Jolla, California, United States
Unknown Facility
Los Angeles, California, United States
Unknown Facility
San Diego, California, United States
Unknown Facility
Santa Monica, California, United States
Unknown Facility
Torrance, California, United States
Unknown Facility
Lone Tree, Colorado, United States
Unknown Facility
Boca Raton, Florida, United States
Unknown Facility
Gainesville, Florida, United States
Unknown Facility
Jacksonville, Florida, United States
Unknown Facility
Largo, Florida, United States
Unknown Facility
Miami, Florida, United States
Unknown Facility
Naples, Florida, United States
Unknown Facility
Port Orange, Florida, United States
Unknown Facility
Winter Park, Florida, United States
Unknown Facility
Athens, Georgia, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Decatur, Georgia, United States
Unknown Facility
Macon, Georgia, United States
Unknown Facility
Idaho Falls, Idaho, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Clive, Iowa, United States
Unknown Facility
Pratt, Kansas, United States
Unknown Facility
Topeka, Kansas, United States
Unknown Facility
Crestview Hills, Kentucky, United States
Unknown Facility
Lexington, Kentucky, United States
Unknown Facility
Louisville, Kentucky, United States
Unknown Facility
Baton Rouge, Louisiana, United States
Unknown Facility
Houma, Louisiana, United States
Unknown Facility
New Orleans, Louisiana, United States
Unknown Facility
Chevy Chase, Maryland, United States
Unknown Facility
Columbia, Maryland, United States
Unknown Facility
Towson, Maryland, United States
Unknown Facility
Boston, Massachusetts, United States
Unknown Facility
Worcester, Massachusetts, United States
Unknown Facility
Ann Arbor, Michigan, United States
Unknown Facility
Chesterfield, Michigan, United States
Unknown Facility
Novi, Michigan, United States
Unknown Facility
Troy, Michigan, United States
Unknown Facility
Ypsilanti, Michigan, United States
Unknown Facility
Rochester, Minnesota, United States
Unknown Facility
Jackson, Mississippi, United States
Unknown Facility
Ocean Springs, Mississippi, United States
Unknown Facility
Columbia, Missouri, United States
Unknown Facility
Kansas City, Missouri, United States
Unknown Facility
Lees Summit, Missouri, United States
Unknown Facility
Urbana, Missouri, United States
Unknown Facility
Las Vegas, Nevada, United States
Unknown Facility
Egg Harbor, New Jersey, United States
Unknown Facility
Marlton, New Jersey, United States
Unknown Facility
Morristown, New Jersey, United States
Unknown Facility
Great Neck, New York, United States
Unknown Facility
New York, New York, United States
Unknown Facility
Poughkeepsie, New York, United States
Unknown Facility
Chapel Hill, North Carolina, United States
Unknown Facility
Charlotte, North Carolina, United States
Unknown Facility
Raleigh, North Carolina, United States
Unknown Facility
Beavercreek, Ohio, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Columbus, Ohio, United States
Unknown Facility
Mentor, Ohio, United States
Unknown Facility
Norman, Oklahoma, United States
Unknown Facility
Oklahoma City, Oklahoma, United States
Unknown Facility
Tulsa, Oklahoma, United States
Unknown Facility
Bend, Oregon, United States
Unknown Facility
Portland, Oregon, United States
Unknown Facility
Malvern, Pennsylvania, United States
Unknown Facility
Philadelphia, Pennsylvania, United States
Unknown Facility
Columbia, South Carolina, United States
Unknown Facility
North Charleston, South Carolina, United States
Unknown Facility
Germantown, Tennessee, United States
Unknown Facility
Nashville, Tennessee, United States
Unknown Facility
Austin, Texas, United States
Unknown Facility
Grapevine, Texas, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
Tyler, Texas, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
Charlottesville, Virginia, United States
Unknown Facility
Chesapeake, Virginia, United States
Unknown Facility
Virginia Beach, Virginia, United States
Unknown Facility
Bellevue, Washington, United States
Unknown Facility
Seattle, Washington, United States
Unknown Facility
Madison, Wisconsin, United States
Unknown Facility
Adelaide, Australia
Unknown Facility
Cairns, Australia
Unknown Facility
Central Queensland M C, Australia
Unknown Facility
Concord, Australia
Unknown Facility
Fremantle, Australia
Unknown Facility
Garran, Australia
Unknown Facility
Liverpool, Australia
Unknown Facility
Malvern, Australia
Unknown Facility
Parkville, Australia
Unknown Facility
Brussels, Belgium
Unknown Facility
Leuven, Belgium
Unknown Facility
Goiânia, Brazil
Unknown Facility
Porto Alegre, Brazil
Unknown Facility
Rio de Janeiro, Brazil
Unknown Facility
São Paulo, Brazil
Unknown Facility
Pleven, Bulgaria
Unknown Facility
Rousse, Bulgaria
Unknown Facility
Sofia, Bulgaria
Unknown Facility
Varna, Bulgaria
Unknown Facility
Calgary, Alberta, Canada
Unknown Facility
Edmonton, Alberta, Canada
Unknown Facility
Vancouver, British Columbia, Canada
Unknown Facility
Brandon, Manitoba, Canada
Unknown Facility
Kingston, Ontario, Canada
Unknown Facility
London, Ontario, Canada
Unknown Facility
Toronto, Ontario, Canada
Unknown Facility
Montreal, Quebec, Canada
Unknown Facility
Saskatoon, Saskatchewan, Canada
Unknown Facility
Saskatoon, Canada
Unknown Facility
Winnipeg, Canada
Unknown Facility
Osijek, Croatia
Unknown Facility
Rijeka, Croatia
Unknown Facility
Zagreb, Croatia
Unknown Facility
Amiens, France
Unknown Facility
Bordeaux, France
Unknown Facility
Caen, France
Unknown Facility
Lille, France
Unknown Facility
Paris, France
Unknown Facility
Rouen, France
Unknown Facility
Vandœuvre-lès-Nancy, France
Unknown Facility
Berlin, Germany
Unknown Facility
Bochum, Germany
Unknown Facility
Frankfurt, Germany
Unknown Facility
Halle, Germany
Unknown Facility
Hamburg, Germany
Unknown Facility
Hanover, Germany
Unknown Facility
Haßloch, Germany
Unknown Facility
Heidelberg, Germany
Unknown Facility
Kiel, Germany
Unknown Facility
Lÿneburg, Germany
Unknown Facility
Mannheim, Germany
Unknown Facility
Minden, Germany
Unknown Facility
München, Germany
Unknown Facility
Münster, Germany
Unknown Facility
Regensburg, Germany
Unknown Facility
Stade, Germany
Unknown Facility
Ulm, Germany
Unknown Facility
Békéscsaba, Hungary
Unknown Facility
Budapest, Hungary
Unknown Facility
Debrecen, Hungary
Unknown Facility
Gyula, Hungary
Unknown Facility
Mosonmagyaróvár, Hungary
Unknown Facility
Pécs, Hungary
Unknown Facility
Szekszárd, Hungary
Unknown Facility
Székesfehérvár, Hungary
Unknown Facility
Reykjavik, Iceland
Unknown Facility
Beer Yaakov, Israel
Unknown Facility
Haifa, Israel
Unknown Facility
Jerusalem, Israel
Unknown Facility
Kfar Saba, Israel
Unknown Facility
Petah Tikva, Israel
Unknown Facility
Rehovot, Israel
Unknown Facility
Tel Aviv, Israel
Unknown Facility
Chikushino-shi, Japan
Unknown Facility
Hachiōji, Japan
Unknown Facility
Hamamatsu, Japan
Unknown Facility
Hirosaki, Japan
Unknown Facility
Hiroshima, Japan
Unknown Facility
Kagoshima, Japan
Unknown Facility
Nishinomiya, Japan
Unknown Facility
Ohtsu, Japan
Unknown Facility
Osaka, Japan
Unknown Facility
Ōita, Japan
Unknown Facility
Sakura, Japan
Unknown Facility
Sapporo, Japan
Unknown Facility
Sendai, Japan
Unknown Facility
Suita-Shi, Japan
Unknown Facility
Tokyo, Japan
Unknown Facility
Tsu, Japan
Unknown Facility
Uruma, Japan
Unknown Facility
Yokkaichi, Japan
Unknown Facility
Yokohama, Japan
Unknown Facility
Yokosuka, Japan
Unknown Facility
Amsterdam, Netherlands
Unknown Facility
Amsterdam-Zuidoost, Netherlands
Unknown Facility
Maastricht, Netherlands
Unknown Facility
Rotterdam, Netherlands
Unknown Facility
Auckland, New Zealand
Unknown Facility
Christchurch, New Zealand
Unknown Facility
Dunedin, New Zealand
Unknown Facility
Grafton, New Zealand
Unknown Facility
Hamilton, New Zealand
Unknown Facility
Hastings, New Zealand
Unknown Facility
Plenty, New Zealand
Unknown Facility
Wellington, New Zealand
Unknown Facility
Bydgoszcz, Poland
Unknown Facility
Elblag, Poland
Unknown Facility
Krakow, Poland
Unknown Facility
Lodz, Poland
Unknown Facility
Warsaw, Poland
Unknown Facility
Moscow, Russia
Unknown Facility
Novosibirsk, Russia
Unknown Facility
Belgrade, Serbia
Unknown Facility
Cape Town, South Africa
Unknown Facility
Durban, South Africa
Unknown Facility
Pretoria, South Africa
Unknown Facility
Daegu, South Korea
Unknown Facility
Gyeonggi-do, South Korea
Unknown Facility
Seoul, South Korea
Unknown Facility
Madrid, Spain
Unknown Facility
Sabadell, Spain
Unknown Facility
Santiago de Compostela, Spain
Unknown Facility
Birmingham, United Kingdom
Unknown Facility
Brighton, United Kingdom
Unknown Facility
Bristol, United Kingdom
Unknown Facility
Cambridge, United Kingdom
Unknown Facility
Gloucester, United Kingdom
Unknown Facility
Harrow, United Kingdom
Unknown Facility
Liverpool, United Kingdom
Unknown Facility
London, United Kingdom
Unknown Facility
Manchester, United Kingdom
Unknown Facility
Norwich, United Kingdom
Unknown Facility
Nottinghamshirecc, United Kingdom
Unknown Facility
Oxford, United Kingdom
Unknown Facility
Shrewsbury, United Kingdom
Unknown Facility
Southampton, United Kingdom
Related Publications (12)
Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C, Miao Y, Ma T, Loftus EV Jr, Sandborn WJ, Danese S, Abreu MT, Sands BE. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis. J Crohns Colitis. 2024 Aug 6;18(7):1091-1101. doi: 10.1093/ecco-jcc/jjae013.
PMID: 38310565DERIVEDColombel JF, Sands BE, Gasink C, Yeager B, Adedokun OJ, Izanec J, Ma T, Gao LL, Lee SD, Targan SR, Ghosh S, Hanauer SB, Sandborn WJ. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 Jan;22(1):144-153.e2. doi: 10.1016/j.cgh.2023.06.014. Epub 2023 Jun 28.
PMID: 37391056DERIVEDDubinsky M, Ma C, Griffith J, Crowell M, Neimark E, Kligys K, O'Connell T. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease. Adv Ther. 2023 Sep;40(9):3896-3911. doi: 10.1007/s12325-023-02546-6. Epub 2023 Jun 27.
PMID: 37368103DERIVEDAdedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022 Oct;44(10):1336-1355. doi: 10.1016/j.clinthera.2022.08.010. Epub 2022 Sep 21.
PMID: 36150926DERIVEDNarula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. United European Gastroenterol J. 2021 Jun;9(5):581-589. doi: 10.1002/ueg2.12094. Epub 2021 Jun 2.
PMID: 34077627DERIVEDSandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm Bowel Dis. 2021 Jun 15;27(7):994-1007. doi: 10.1093/ibd/izaa236.
PMID: 32964215DERIVEDLi K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology. 2019 Oct;157(4):1019-1031.e7. doi: 10.1053/j.gastro.2019.06.037. Epub 2019 Jul 4.
PMID: 31279870DERIVEDGhosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf. 2019 Jun;42(6):751-768. doi: 10.1007/s40264-019-00797-3.
PMID: 30739254DERIVEDRutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018 Oct;155(4):1045-1058. doi: 10.1053/j.gastro.2018.06.035. Epub 2018 Aug 29.
PMID: 29909019DERIVEDAdedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 May;154(6):1660-1671. doi: 10.1053/j.gastro.2018.01.043. Epub 2018 Feb 1.
PMID: 29409871DERIVEDHibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res. 2017 Oct;15(4):475-486. doi: 10.5217/ir.2017.15.4.475. Epub 2017 Oct 23.
PMID: 29142515DERIVEDFeagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI-IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
PMID: 27959607DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The global study was interrupted due to issues with the clinical supply.
Results Point of Contact
- Title
- Vice President
- Organization
- Janssen Research & Development, LLC
Study Officials
- STUDY DIRECTOR
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 7, 2011
First Posted
June 8, 2011
Study Start
July 1, 2011
Primary Completion
August 1, 2014
Study Completion
October 1, 2014
Last Updated
January 6, 2017
Results First Posted
January 6, 2017
Record last verified: 2016-11